Pharma innovative research boosted with gut and gut-brain axis

Make major scientific breakthroughs in your innovative pharma research

Thanks to our holistic approach on the gut and gut-brain axis, we accompany your innovation process by designing and implementing experimental protocols adapted to your pharmaceutical objectives and development pipeline. To that end, we use our expertise to offer a wide range of tests to provide you with real differentiation opportunities:

  • Screening of potential assets
  • Improvement of lead profiling and selection
  • Comparison of various drug candidates in different organs
  • Characterization and consolidation of mechanisms of action
  • Characterization and consolidation of therapeutics effects
  • Repositioning of your compounds
CRO for PHARMA

Reveal the potential of your pharmaceutical leads thanks to the gut and the gut-organ axis!

New legislation, patent expiration and rising healthcare costs are demanding decisive changes in the global pharmaceutical industry.

Your companies evolve in a very competitive environment.  New and disruptive approaches are needed to pursue a holistic medical approach which integrates the digestive sphere and its impacts on the related peripheral organs.

Gut and gut-organ preclinical studies boost the development of your molecules

Enterosys is a CRO rooted in the gut to support innovative pharma research

Enterosys offers rapid and innovative protocols for the analysis of physiological parameters in real time. Our approaches allow you to save time and costs in the development of your therapeutics to quickly position or reposition your assets. We help researchers to advance science and improve precision health much faster.

Our holistic gut-organ approach demonstrates the beneficial effects of molecules of interest and may also detect potential side effects on other organs very early in the development process. Our cutting-edge expertise allows you to leverage your molecules and to de-risk innovation.

OUR KEY SCIENTIFIC FINDINGS ABOUT THE GUT

Targeting our second brain to fight diabetes

Targeting our second brain to fight diabetes

The enteric nervous system (ENS) plays a key role in controlling the gut-brain axis under normal and pathological conditions, such as type 2 diabetes. The discovery of intestinal actors, such as enterosynes, able to modulate the ENS-induced duodenal contraction is considered a pioneering approach.

Highlighting the potential neurologic side effects of Beta-Blockers

Highlighting the potential neurologic side effects of Beta-Blockers

In addition to their classical mode of action in the brain, circulating factors may modulate the release of reactive oxygen/nitrogen species (ROS/RNS) from endothelial cells that compose the blood-brain-barrier without entering the brain. Due to their high capacity to diffuse across membranes, ROS/RNS can reach neurons and modify their activity. This study investigates other mechanisms of actions in which beta-blockers may display a central effect without crossing the blood brain barrier.